


## IN THE CLAIMS

1. – 14. (Cancelled)

15. (Previously Presented) A compound of formula (Ib):



wherein  $R^a$  is selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkynyl, hydroxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy $C_1$ - $C_6$  alkyl, perfluoro $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylamino, di- $C_1$ - $C_6$  alkylamino, amino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, di- $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkylthio;  $R^b$  is selected from hydrogen, halogen, hydroxy, ( $C_1$ - $C_6$ )alkoxy cyano, nitro, amino, hydroxycarbonyl,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkenyl,  $C_1$ - $C_6$  alkynyl,  $C_1$ - $C_6$  alkoxy, hydroxy $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy $C_1$ - $C_6$  alkyl, perfluoro  $C_1$ - $C_6$  alkyl, perfluoro $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylamino, di- $C_1$ - $C_6$  alkylamino, amino $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, di- $C_1$ - $C_6$  alkylamino $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkylthio; or a pharmaceutically acceptable salt thereof.

16. - 17. (Cancelled)

18. (Withdrawn) A compound of formula (1b) according to claim 15 which is selected from the group consisting of:

(2S,4S)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; and  
(2S,4S)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid; or a pharmaceutically acceptable salt thereof.

19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

21. (Previously Presented) A pharmaceutical composition comprising a compound of formula (1b) according to claim 15, or a pharmaceutically acceptable salt thereof, and at least one other therapeutically active agent.

22. (Previously Presented) A pharmaceutical composition according to claim 21, wherein the other therapeutically active agent is a PDEV inhibitor selected from sildenafil, vardenafil, tadalafil, 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-*d*]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine, 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one and 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one.

23. - 26. (Cancelled)

27. (Previously Presented) The compound (2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

28. (Withdrawn) The compound (2*S*,4*S*)-4-(2,3-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid, a pharmaceutically acceptable salt thereof.

29. (Withdrawn) The compound (2*S*,4*S*)-4-(2,5-Difluoro-benzyl)-pyrrolidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

30. (Previously Presented) The salt, (2*S*,4*S*)-4-(3-Fluoro-benzyl)-pyrrolidine-2-carboxylic acid mono hydrochloride salt.